Hospital Universitario Marques De Valdecilla — Clinical Trial Site

585 Registered trials

229 Currently recruiting

Organisation

Hospital Universitario Marques De Valdecilla

Location

Santander, Spain

Identifier

ORG-100028562

Address

Avenida Valdecilla Sn, 39008, Spain

Departments

-
#2029:Hematology
#2608: Reumatología
#3406 - Reumatología
#3406:Reumatología
#3455: Endocrinología
#40617:Reumatología
#4209:Servicio de Oncología
#7006: Oncología Médica
#724005:Neurología
1306: Hematología
1312: Hematología
1406: Reumatología
172416: Hematología
2456: Reumatología
2504:Oncología
3110: neurologia
3406: Reumatología
4209: Medicina Interna
4255:Reumatologia
601: Reumatología
7003: Oncología Médica
7005; Oncology
7007: Oncología Médica
7008: Oncología Médica
7009: Oncología Médica
7014: Oncología Médica
7015_Neumología
724003; Hematología
724004; Pulmonology
Alergia
Aparato Digestivo
Cardiología
Cardiology
Coronary Intervention
Department of Urology
Dept. of Rheumatology
Dermatologia
Digestive
Digestive Department
Digestive Diseases
Digestive Service
Digestive system
Digestive system service
Digestivo
Digestivo Hepatologia
disease infection
Endocrinology
Endocrinology and Matabolism
Endocrinology and metabolism
Endocrinology, Diabetes & Nutrition
Endocrinology, Diabetes & Nutrition Department
Endocrinology, Diabetes and Nutrition
Endrocrinology
ES053A: Hematología
ES10002: Aparato Digestivo
ES10005: Aparato Digestivo
ES10022: Hematología
Gastroenterologia y Hepatologia
Gastroenterology
Gastroenterology and Hepatology
Gastroenterology and Hepatology Service
Gastroenterology Department
Gastroenterologyand Hepatology
Gastroenteroloy and Hepatology department
Haematology
Haematology & Hemotherapy Department
Hematologia
Hematology
Hematology & Hemotherapy
Hematology and Hemotherapy
Hematology and Hemotherapy Service.
Hematology department
Hematology service
Hematology unit
Hepatology
Hospital Universitario Marqués de Valdecilla
Hospital Universitario Marqués de Valdecilla Hospital Universitario Marques De Valdecilla (#1)
HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA-Valdec
Hospital Universitario Marques De Valdecilla( #1)
Infecciosas
Infectious Disease Department
Infectious Diseases
Infectious Diseases Unit
Inmunology
Internal Medicine
Internal Medicine department
Medical Oncolgy Service
Medical Oncology
Medical Oncology Department
Medical Oncology Service
Medical Onkology Service
Medicina Interna
Medicina Nuclear
N/A
NA
Nefrology
Neonatology department
Nephrology
NEUMOLOGÍA
Neumology
Neumology and Lung Transplant
Neurología
neurologia pediatrica
Neurology
Oncolgy
Oncología
Oncología - Unidad de Inv. Clínica
Oncologia Medica
Oncology
Oncology Department
Oncology service
ORL
Otolaryngology (ENT Department)
Otorhinolaryngolog Service
pediatric oncology
Pediatric oncology and hematology department
Pneumology
Pneumology Department
Pneumology Service
Pneumonology
Preventive medicine
PSIQUIATRIA
Pulmonary
Pulmonary Medicine
Pulmonología
Pulmonologist
Pulmonology
Pulmonology department
Respiratory medicine
Reumathology
Reumatología
Rheumatology
Rheumatology Service
Servicio de digestivo
Servicio de Neumología. Tx Pulmonar
Servicio de Aparato Digestivo
Servicio de Cardiología
Servicio de Dermatologia
Servicio de Endocrinologia
Servicio de Endocrinología y Nutrición
Servicio de Endocrinología, Diabetes y Nutrición
Servicio de Enfermedades Infecciosas
Servicio de Hematologia
Servicio de Nefrología – ed. 2 de Noviembre 1ª Planta – Avd. Valdecilla s/n. 39008 Santander, Spain
Servicio de Neumología
Servicio de Neurología
Servicio de Oncología
Servicio de Oncologia Medica
Servicio de Reumatologia
Servicio de Reumotología
UCG Enfermedades Infecciosas, Microbiología y Medicina preventiva
Unidad de Ensayos Clínicos
Unidad de Ensayos Clínicos.
Unidad de Gestión Clínica de Enfermedades Infecciosas, Microbiología y Medicina Preventiva.
Uro-Oncology
Urology

Clinical trials at this site (585)

Search interface

A Study of Vepugratinib (LY3866288) in Participants with Cancer in the Urinary Tract ( FORAGER-2 ) Pending

2025-522855-25-00 Carcinoma, Transitional Cell 5
An extension study to investigate the long-term safety and tolerability of itepekimab in adult participants with inadequately controlled chr… Pending

2025-522983-33-00 Chronic rhinosinusitis with nasal polyps 5
Phase Ib Dose-Ranging Study of the Safety, PK, PD & Efficacy of the Activin Signaling Inhibitor HS235 vs placebo added to background therapy… Pending

2025-523010-89-00 Pulmonary arterial hypertension 3
A Randomized, Placebo-controlled, Parallel Phase 2a Dose-ranging Study to Investigate the Efficacy, Safety, and Tolerability of Topical HT-0… Pending

2025-523058-16-00 Skin Toxicities Associated with Epidermal Growth Factor 4
A trial to learn how well AZD0120 works and how safe it is in people with relapsed or refractory multiple myeloma. Pending

2025-523285-25-00 Relapsed or Refractory Multiple Myeloma 5
Symbiotic-GU-06-A Study to Learn About the Study Medicine PF-08634404 Alone or In Combination With Enfortumab Vedotin in Adult Participants … Pending

2025-523523-21-00 Locally Advanced or Metastatic Urothelial Cancer 9
A study to investigate dabogratinib (TYRA-300) in participants with Low Grade Upper Tract Urothelial Carcinoma Pending

2025-523539-20-00 Low Grade Upper Tract Urothelial Carcinoma 4
A Phase 1 Study of AIR-001 in Adults with AATD. Pending

2025-523558-14-00 Alpha-1 Antitrypsin Deficiency 1
SAVE trial Pending

2025-523709-13-00 Acute ischemic stroke 5
A Randomized, Double-Blind, Phase 3 Study of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treat… Pending

2025-523735-19-00 Metastatic Microsatellite Stable Colorectal Cancer 5
A study to test single and multiple doses of MER511 given to adults with Graves’ disease Pending

2025-523823-23-00 Graves’ disease 1
A study in people with advanced extrapulmonary neuroendocrine cancer to compare obrixtamig plus carboplatin and etoposide treatment with sta… Pending

2025-523869-22-00 advanced or metastatic extrapulmonary neuroendocrine ca 5
AMG 436 as monotherapy and combination therapy in participants with Microsatellite Instability-High/Mismatch Repair Deficient Solid Tumors… Pending

2025-524056-63-00 microsatellite instability high/mismatch repair deficie 1
Phase III randomized international open label clinical trial of treatment Intensification with docetaxel plus apalutamide in patients with m… Pending

2025-524408-30-01 Metastatic hormone-sensitive prostate cancer 5
PHASE IB/II STUDY TO EVALUATE SAFETY AND PRELIMINARY EFFICACY OF ZANIDATAMAB IN COMBINATION WITH TUCATINIB AND CHEMOTHERAPY (CAPECITABINE OR… Pending

2025-524613-89-00 HER2 positive advanced breast cancer 9
Immunosuppressant Discontinuation in Elderly patients with ulcerative colitis And long-term remission Pending

2025-524675-23-00 Ulcerative Colitis 6
A trial to learn how safe different combinations of anti-cancer drugs are and how well they work in adults with advanced or metastatic non-s… Pending

2025-524843-11-00 Non-Small Cell Lung Cancer 4
A Study of KT-621 Administered Orally to Adult Participants with Moderate to Severe Eosinophilic Asthma Recruiting

2025-523180-38-00 Uncontrolled Moderate to Severe Eosinophilic Asthma 4 2026-05-21
AURA-IPF: A Randomized Phase 2 Study to evaluate the safety and efficacy of AP02 (nintedanib solution) in IPF Recruiting

2025-523431-19-00 Idiopathic Pulmonary Fibrosis (IPF) 4 2026-05-20
A Global Study Testing the New Drug Olverembatinib combined with chemotherapy for Patients with Newly Diagnosed Philadelphia Chromosome-Pos… Recruiting

2024-511496-14-00 Newly Diagnosed Philadelphia Chromosome-Positive Acute 5 2026-05-14
An open-label extension (OLE) trial to evaluate long-term safety and tolerability of pelacarsen (TQJ230) Recruiting

2024-519870-38-00 Atherosclerotic cardiovascular disease (ASCVD) 5 2026-05-11
Long-term safety and efficacy evaluation of lunsekimig (SAR443765) in adult participants with moderate-to-severe asthma. Recruiting

2025-522896-27-00 Asthma 4 2026-05-11
A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin ( ENLIGHTEN-6 ) Recruiting

2025-523659-73-00 Obesity 5 2026-05-11
A clinical study to evaluate the effects of RO7795068 in participants with obesity or overweight without type 2 diabetes. Recruiting

2025-523104-71-00 Obesity or Overweight Without Type 2 Diabetes 5 2026-05-08